Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency

Detalles Bibliográficos
Autores principales: Martin, Adriana, Lavoie, Louis, Goetghebeur, Mireille, Schellenberg, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487819/
http://dx.doi.org/10.1186/1710-1492-8-S1-A20
_version_ 1782248522744070144
author Martin, Adriana
Lavoie, Louis
Goetghebeur, Mireille
Schellenberg, Robert
author_facet Martin, Adriana
Lavoie, Louis
Goetghebeur, Mireille
Schellenberg, Robert
author_sort Martin, Adriana
collection PubMed
description
format Online
Article
Text
id pubmed-3487819
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34878192012-11-08 Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency Martin, Adriana Lavoie, Louis Goetghebeur, Mireille Schellenberg, Robert Allergy Asthma Clin Immunol Meeting Abstract BioMed Central 2012-11-02 /pmc/articles/PMC3487819/ http://dx.doi.org/10.1186/1710-1492-8-S1-A20 Text en Copyright ©2012 Martin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Abstract
Martin, Adriana
Lavoie, Louis
Goetghebeur, Mireille
Schellenberg, Robert
Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
title Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
title_full Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
title_fullStr Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
title_full_unstemmed Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
title_short Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
title_sort economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487819/
http://dx.doi.org/10.1186/1710-1492-8-S1-A20
work_keys_str_mv AT martinadriana economicbenefitofsubcutaneousrapidpushversusintravenousimmunoglobulininfusiontherapyinadultpatientswithprimaryimmunedeficiency
AT lavoielouis economicbenefitofsubcutaneousrapidpushversusintravenousimmunoglobulininfusiontherapyinadultpatientswithprimaryimmunedeficiency
AT goetghebeurmireille economicbenefitofsubcutaneousrapidpushversusintravenousimmunoglobulininfusiontherapyinadultpatientswithprimaryimmunedeficiency
AT schellenbergrobert economicbenefitofsubcutaneousrapidpushversusintravenousimmunoglobulininfusiontherapyinadultpatientswithprimaryimmunedeficiency

Ejemplares similares